Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Andrzej J. Jakubowiak, Ivan Houisse, István Májer, Ágnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States'. Together they form a unique fingerprint.

Medicine & Life Sciences